Bailard Inc. Sells 1,241 Shares of Pfizer Inc. (NYSE:PFE)

Bailard Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 187,943 shares of the biopharmaceutical company’s stock after selling 1,241 shares during the quarter. Bailard Inc.’s holdings in Pfizer were worth $11,098,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ibex Wealth Advisors bought a new stake in Pfizer during the third quarter worth $26,000. Econ Financial Services Corp bought a new stake in Pfizer during the fourth quarter worth $31,000. PYA Waltman Capital LLC bought a new stake in Pfizer during the fourth quarter worth $31,000. TFO TDC LLC grew its holdings in Pfizer by 126.9% during the fourth quarter. TFO TDC LLC now owns 667 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 373 shares in the last quarter. Finally, MFA Wealth Advisors LLC bought a new position in Pfizer in the 3rd quarter valued at $38,000. Hedge funds and other institutional investors own 66.50% of the company’s stock.

PFE traded down $0.47 during trading on Friday, reaching $49.92. 22,423,685 shares of the company were exchanged, compared to its average volume of 24,886,970. The company’s 50-day moving average is $51.27 and its two-hundred day moving average is $51.84. Pfizer Inc. has a 12-month low of $38.47 and a 12-month high of $61.71. The company has a market cap of $281.94 billion, a price-to-earnings ratio of 11.45, a P/E/G ratio of 0.59 and a beta of 0.76. The company has a quick ratio of 1.19, a current ratio of 1.40 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFEGet Rating) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing the consensus estimate of $1.80 by ($0.18). Pfizer had a net margin of 26.97% and a return on equity of 39.33%. The business had revenue of $25.66 billion during the quarter, compared to analysts’ expectations of $24.73 billion. During the same period in the previous year, the business earned $0.93 EPS. The business’s revenue was up 76.8% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 6.69 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Friday, May 13th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Thursday, May 12th. This represents a $1.60 annualized dividend and a dividend yield of 3.21%. Pfizer’s payout ratio is currently 36.70%.

A number of brokerages have issued reports on PFE. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating and set a $52.00 price objective for the company. in a research note on Tuesday, February 15th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Mizuho reduced their price objective on Pfizer from $56.00 to $55.00 in a research note on Thursday, February 10th. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research note on Tuesday, May 3rd. Finally, BMO Capital Markets upped their price target on Pfizer from $60.00 to $76.00 in a research report on Friday, January 14th. Eleven analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $57.05.

In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.